全文获取类型
收费全文 | 1094篇 |
免费 | 78篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 43篇 |
妇产科学 | 57篇 |
基础医学 | 118篇 |
口腔科学 | 28篇 |
临床医学 | 141篇 |
内科学 | 266篇 |
皮肤病学 | 34篇 |
神经病学 | 20篇 |
特种医学 | 126篇 |
外科学 | 48篇 |
综合类 | 24篇 |
预防医学 | 56篇 |
眼科学 | 4篇 |
药学 | 50篇 |
1篇 | |
中国医学 | 3篇 |
肿瘤学 | 155篇 |
出版年
2023年 | 4篇 |
2021年 | 15篇 |
2020年 | 6篇 |
2019年 | 9篇 |
2018年 | 18篇 |
2017年 | 6篇 |
2016年 | 9篇 |
2015年 | 16篇 |
2014年 | 22篇 |
2013年 | 34篇 |
2012年 | 24篇 |
2011年 | 35篇 |
2010年 | 51篇 |
2009年 | 51篇 |
2008年 | 37篇 |
2007年 | 48篇 |
2006年 | 40篇 |
2005年 | 46篇 |
2004年 | 36篇 |
2003年 | 22篇 |
2002年 | 21篇 |
2001年 | 23篇 |
2000年 | 26篇 |
1999年 | 34篇 |
1998年 | 44篇 |
1997年 | 54篇 |
1996年 | 48篇 |
1995年 | 26篇 |
1994年 | 33篇 |
1993年 | 27篇 |
1992年 | 32篇 |
1991年 | 21篇 |
1990年 | 28篇 |
1989年 | 33篇 |
1988年 | 24篇 |
1987年 | 17篇 |
1986年 | 22篇 |
1985年 | 16篇 |
1984年 | 22篇 |
1983年 | 16篇 |
1982年 | 18篇 |
1981年 | 15篇 |
1980年 | 10篇 |
1979年 | 3篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1973年 | 3篇 |
1972年 | 5篇 |
1971年 | 4篇 |
排序方式: 共有1177条查询结果,搜索用时 597 毫秒
71.
F. Germán Rodríguez-González Anieta M. Sieuwerts Marcel Smid Maxime P. Look Marion E. Meijer-van Gelder Vanja de Weerd Stefan Sleijfer John W. M. Martens John A. Foekens 《Breast cancer research and treatment》2011,127(1):43-51
MicroRNAs (miRNAs) are small RNA molecules that modulate gene expression and which have been implicated in cancer. We evaluated
whether five candidate predictive miRNAs, derived from a pilot study in which 249 miRNAs were assayed, were associated with
clinical benefit of tamoxifen therapy in advanced breast cancer. These five miRNAs were measured in an independent series
of 246 estrogen receptor (ER)-positive primary breast tumors of patients who received tamoxifen for advanced disease by quantitative
Real Time PCR. Univariate analysis showed that higher expression levels of hsa-miR-30a-3p, hsa-miR-30c, and hsa-miR-182 were
significantly associated with benefit of tamoxifen treatment and with longer PFS (all P-values <0.01). In multivariate analysis, corrected for the traditional predictive factors, only hsa-miRNA-30c was an independent
predictor (P-value <0.01). Finally, in an attempt to understand the biology connected to this miRNA, Global testing pathway analysis showed
an association of hsa-miRNA-30c expression with HER and RAC1 signaling pathways. We identified hsa-miRNA-30c as an independent
predictor for clinical benefit of tamoxifen therapy in patients with advanced breast cancer. Assessment of tumor levels and
connected pathways could be helpful to improve treatment strategies. 相似文献
72.
73.
Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response 总被引:1,自引:0,他引:1
Jozien Helleman Maurice P H M Jansen Kirsten Ruigrok-Ritstier Iris L van Staveren Maxime P Look Marion E Meijer-van Gelder Anieta M Sieuwerts Jan G M Klijn Stefan Sleijfer John A Foekens Els M J J Berns 《Clinical cancer research》2008,14(17):5555-5564
PURPOSE: We previously discovered an extracellular matrix (ECM) gene cluster associated with resistance to first-line tamoxifen therapy of patients with metastatic breast cancer. In this study, we determined whether the six individual ECM genes [collagen 1A1 (COL1A1), fibronectin 1 (FN1), lysyl oxidase (LOX), secreted protein acidic cysteine-rich (SPARC), tissue inhibitor of metalloproteinase 3 (TIMP3), and tenascin C (TNC)] were associated with treatment response, prognosis, or both. EXPERIMENTAL DESIGN: In 1,286 primary breast tumors, mRNA expression (quantitative real-time PCR) was related to clinicopathologic factors and disease outcome in univariate and multivariate analysis including traditional factors. RESULTS: TIMP3, FN1, LOX, and SPARC expression levels (continuous variables) were significantly associated with distant metastasis-free survival (MFS) in 680 lymph node-negative untreated patients (P<0.03). Using a calculated linear prognostic score, these patients were evenly divided into five prognostic groups with a significant difference in 10-year MFS of approximately 40% between the two extreme prognostic groups. Furthermore, high TNC expression as continuous variable was associated with (a) shorter MFS in 139 estrogen receptor-positive and lymph node-positive patients who received adjuvant tamoxifen therapy (hazard ratio, 1.53; P=0.001), and (b) no clinical benefit (odds ratio, 0.81; P=0.035) and shorter progression-free survival (hazard ratio, 1.19; P=0.002) in 240 patients in whom recurrence was treated with tamoxifen as first-line monotherapy. These results were also significant in multivariate analyses. CONCLUSION: FN1, LOX, SPARC, and TIMP3 expression levels are associated with the prognosis of patients with breast cancers, whereas TNC is associated with resistance to tamoxifen therapy. Further validation and functional studies are necessary to determine the use of these ECM genes in decisions regarding treatment and whether they can serve as targets for therapy. 相似文献
74.
MP Richardson TJ Williamson SW Lenton MJ Tarlow PT Rudd 《Archives of disease in childhood》1995,72(4):294-297
Transient evoked otoacoustic emissions (TEOAEs) are low amplitude sound waves produced by the healthy cochlea. They can be recorded with a microphone in the external ear. TEOAEs are abolished by hearing losses of 30 dB or more. The feasibility of using TEOAEs as a screening test for hearing loss in children was studied. TEOAE recordings were attempted in 56 children attending an audiology clinic. Recordings were possible from both ears in 52 children; of these 104 ears, 32 had hearing deficits of 30 dB or more. Hearing status was compared with the results of six TEOAE screening criteria. All criteria had a sensitivity of 1.00. Four standard TEOAE criteria yielded specificities of 0.46-0.58. Two new criteria derived from analysis of limited frequencies from the TEOAE waveform gave specificities of 0.76 and 0.82. It can be concluded that, when appropriate pass/fail criteria are employed, TEOAEs are a feasible screening test in children. 相似文献
75.
Garcia AA Bookman MA Rodriguez-Rodriguez L Mutch DG Look KY;Gynecologic Oncology Group 《Investigational new drugs》2002,20(4):383-387
Objective: Although improvementshave been made in the management ofpatients with advanced ovarian cancer,long-term survivors are still uncommon. Gemcitabine and prolonged oral etoposidehave shown reproducible single-agentactivity in patients withplatinum/paclitaxel-resistant ovariancancer. This, combined with preclinicalsynergism, prompted the GynecologicOncology Group to determine the maximumtolerated dose (MTD) of this combination.
Methods: Eligible patients hadrecurrent epithelial ovarian cancer,primary papillary peritoneal, or fallopiantube carcinoma. All had received priorplatinum/paclitaxel-based chemotherapy andhad adequate hepatic, renal and bone marrowfunction. Oral etoposide was administeredat 50 mg/m2 for ten days, with threeproposed dose levels for gemcitabine ondays 1 and 8: 400, 550 and 700 mg/m2. Cycles were to be repeated every 28 days. Three patients were to enter at each doselevel.
Results: Patients were enrolled onlyto dose level 1 as this dose exceeded MTD. Of six patients initially enrolled, one wasremoved after three days with fever,ascites and decreased albumin believed notto be treatment related. Five patientswere evaluable for toxicity and response. One of the first three patients developeddose limiting toxicity (DLT) manifested asgrade 4 neutropenia. A second DLT(neutropenic fever and thrombocytopeniaassociated with bleeding) occurred amongthe next three patients; therefore, MTD wasreached at dose level 1. Grade 4toxicities included episodes of neutropenia(4) and thrombocytopenia (3). No objectiveresponse was observed.
Conclusions: Oral etoposide andgemcitabine at this dose and schedule wasassociated with substantial toxicity inthis population. Patients who are previously treated withplatinum/paclitaxel-based chemotherapy maybe at particular risk for toxicity. 相似文献
76.
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance 总被引:9,自引:0,他引:9
Luo LY Diamandis EP Look MP Soosaipillai AP Foekens JA 《British journal of cancer》2002,86(11):1790-1796
The human tissue kallikreins are secreted serine proteases, encoded by a group of homologous genes clustered in tandem on chromosome 19q13.3-4. Human kallikrein 6 and human kallikrein 10 are two new members of this family. Recently, we developed highly sensitive and specific immunofluorometric assays for human kallikrein 6 and human kallikrein 10, which allow for their quantification in tissue extracts and biological fluids. Both human kallikrein 6 and human kallikrein 10 are found to be down-regulated in breast cancer cell lines, suggesting that they may be involved in breast cancer pathogenesis and progression. In this study, we investigated the potential value of human kallikrein 6 and human kallikrein 10 as prognostic and predictive factors in breast cancer. We quantified human kallikrein 6 and human kallikrein 10 protein levels in 749 breast tumour cytosolic extracts and correlated this data with various clinicopathological variables and patient outcomes. Human kallikrein 6 and human kallikrein 10 are positively correlated with each other. Higher human kallikrein 6 and human kallikrein 10 protein levels are associated with younger age, pre-menopausal, status and tumours which are negative for oestrogen and progesterone receptors. No correlation was found between human kallikrein 6 and human kallikrein 10 levels and tumour size, grade, and nodal status. Survival analysis showed that neither human kallikrein 6 nor human kallikrein 10 are related to the rate of relapse-free and overall survival. In the analysis with respect to response to tamoxifen therapy, although human kallikrein 6 levels were not associated with tamoxifen responsiveness, higher levels of human kallikrein 10 were significantly associated with a poor response rate. This association remained significant in the multivariate analysis. Furthermore, higher human kallikrein 10 levels were significantly related with a short progression-free and post-relapse overall survival after start of tamoxifen treatment for advanced disease. Taken together, our results suggest that although human kallikrein 6 and human kallikrein 10 are not prognostic markers for breast cancer, human kallikrein 10 is an independent predictive marker for response of tamoxifen therapy. 相似文献
77.
78.
79.
80.
Twiss JM Duma S Look V Shaffer GS Watkins AC 《Public health reports (Washington, D.C. : 1974)》2000,115(2-3):125-133
California Healthy Cities and Communities is the longest running statewide program of its kind in the nation. After providing a brief history the authors give an overview of the supporting activities and resources the Program provides to Healthy Cities and Communities initiatives throughout California. 相似文献